.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF01_Tretinoin.Tretinoin

Information

Tretinoin (all-trans retinoic acid) is a derivative of vitamin A used primarily in the treatment of acute promyelocytic leukemia (APL) as a differentiation agent under the ATC code L01XF01. Its use in oncology is distinct from topical use for acne or dermatology. It is approved for intravenous and oral administration in acute promyelocytic leukemia.

Pharmacokinetics

Reported for adult patients with acute promyelocytic leukemia receiving oral tretinoin therapy.

References

1. Napolitano, M, et al., & Patruno, C (2022). Alitretinoin for the treatment of severe chronic eczema of the hands. Expert opinion on pharmacotherapy 23(2) 159–167. DOI:10.1080/14656566.2021.1998457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34789049

2. Regazzi, MB, et al., & Liberati, AM (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clinical drug investigation 16(1) 25–33. DOI:10.2165/00044011-199816010-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18370515

3. Rigas, JR, et al., & Warrell, RP (1993). Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. Journal of the National Cancer Institute 85(23) 1921–1926. DOI:10.1093/jnci/85.23.1921 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8230282

Revisions

• 06/2025 initial generated model